Doximity (NYSE:DOCS) Price Target Lowered to $28.00 at JPMorgan Chase & Co.

Doximity (NYSE:DOCS) had its price target reduced by JPMorgan Chase & Co. from $33.00 to $28.00 in a report published on Thursday,Benzinga reports. They currently have a neutral rating on the stock.

A number of other equities analysts have also commented on the stock. Leerink Partners cut their price target on shares of Doximity from $31.00 to $25.00 and set an “outperform” rating on the stock in a report on Thursday. BTIG Research downgraded shares of Doximity from a “buy” rating to a “neutral” rating in a research note on Thursday. Robert W. Baird reissued a “neutral” rating and set a $18.00 target price (down from $40.00) on shares of Doximity in a research note on Thursday. KeyCorp downgraded shares of Doximity from an “overweight” rating to a “sector weight” rating in a research note on Thursday. Finally, Truist Financial reissued a “hold” rating and set a $19.00 target price (down from $29.00) on shares of Doximity in a research note on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and thirteen have assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $30.62.

Doximity Trading Down 23.3%

Shares of NYSE:DOCS opened at $17.94 on Thursday. The firm has a market capitalization of $3.31 billion, a price-to-earnings ratio of 18.12, a PEG ratio of 1.66 and a beta of 1.36. The business’s fifty day simple moving average is $24.09. Doximity has a 52 week low of $17.15 and a 52 week high of $76.51.

Doximity announced that its board has initiated a stock buyback plan on Thursday, February 5th that permits the company to buyback $500.00 million in outstanding shares. This buyback authorization permits the company to purchase up to 8% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s management believes its stock is undervalued.

Insiders Place Their Bets

In related news, Director Kira Scherer Wampler sold 9,000 shares of the firm’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $26.06, for a total transaction of $234,540.00. Following the completion of the transaction, the director owned 19,839 shares of the company’s stock, valued at $517,004.34. This trade represents a 31.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Siddharth Sitaram sold 2,427 shares of the firm’s stock in a transaction dated Friday, April 10th. The shares were sold at an average price of $21.09, for a total value of $51,185.43. Following the transaction, the insider directly owned 86,705 shares of the company’s stock, valued at $1,828,608.45. This represents a 2.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 18,055 shares of company stock valued at $456,061. 31.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Doximity

Several hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC lifted its stake in Doximity by 29.4% in the 1st quarter. Renaissance Technologies LLC now owns 3,059,749 shares of the company’s stock worth $71,292,000 after acquiring an additional 694,300 shares in the last quarter. Caxton Associates LLP purchased a new stake in Doximity in the 1st quarter worth about $1,809,000. Bank of Nova Scotia purchased a new stake in Doximity in the 1st quarter worth about $10,130,000. Sei Investments Co. lifted its stake in Doximity by 23.2% in the 1st quarter. Sei Investments Co. now owns 96,808 shares of the company’s stock worth $2,256,000 after acquiring an additional 18,216 shares in the last quarter. Finally, Lido Advisors LLC lifted its stake in Doximity by 16.8% in the 1st quarter. Lido Advisors LLC now owns 12,657 shares of the company’s stock worth $295,000 after acquiring an additional 1,822 shares in the last quarter. 87.19% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Doximity

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Doximity reported adjusted EPS of $0.26, ahead of one analyst estimate, and revenue rose 5.1% year over year to $145.37 million, showing the core business is still growing. Doximity Earnings Report
• Positive Sentiment: Commentary around AI adoption and customer growth suggests Doximity’s platform remains engaged with clinicians, which could support longer-term monetization. Zacks Coverage
• Neutral Sentiment: The company maintained strong profitability metrics, including a 23.84% return on equity and 37.54% net margin, but those figures were overshadowed by weaker near-term outlook commentary. Fiscal Q4 Earnings Snapshot
• Negative Sentiment: Doximity missed the broader analyst consensus on EPS, which disappointed traders looking for a stronger earnings beat. Doximity Lags Q4 Earnings Estimates
• Negative Sentiment: Most importantly, fiscal 2027 revenue guidance came in below Wall Street expectations, reinforcing concerns that growth is slowing while AI-related investment is pressuring margins. Doximity Q4 2026 Earnings Call Transcript
• Negative Sentiment: Multiple analysts cut price targets after the report, including JPMorgan, Truist, BMO Capital, Mizuho, and Needham, adding to the negative sentiment around the stock. Analyst Target Cuts
• Negative Sentiment: Unusual put-option buying and an insider share sale added to the cautious tone, even though the insider transaction was part of a pre-arranged trading plan. Insider Trade Disclosure

About Doximity

Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.

The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.